687 related articles for article (PubMed ID: 15667617)
21. Usefulness of Tacrolimus without Basiliximab in Well-Matched Living-Donor Renal Transplant Recipients in Korea.
Baek CH; Kim JH; Yu H; Shin E; Cho H; Kim H; Yang WS; Han DJ; Park SK
Exp Clin Transplant; 2016 Aug; 14(4):389-93. PubMed ID: 27228054
[TBL] [Abstract][Full Text] [Related]
22. Triple immunosuppression with or without basiliximab in pediatric renal transplantation: acute rejection rates at one year.
Duzova A; Buyan N; Bakkaloglu M; Dalgic A; Soylemezoglu O; Besbas N; Bakkaloglu A
Transplant Proc; 2003 Dec; 35(8):2878-80. PubMed ID: 14697926
[TBL] [Abstract][Full Text] [Related]
23. Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
Gallon LG; Winoto J; Chhabra D; Parker MA; Leventhal JR; Kaufman DB
Transplantation; 2007 May; 83(10):1324-9. PubMed ID: 17519781
[TBL] [Abstract][Full Text] [Related]
24. Rabbit antithymocyte globulin versus basiliximab in renal transplantation.
Brennan DC; Daller JA; Lake KD; Cibrik D; Del Castillo D;
N Engl J Med; 2006 Nov; 355(19):1967-77. PubMed ID: 17093248
[TBL] [Abstract][Full Text] [Related]
25. Tacrolimus-based, steroid-free regimens in renal transplantation: 3-year follow-up of the ATLAS trial.
Krämer BK; Klinger M; Vítko Š; Glyda M; Midtvedt K; Stefoni S; Citterio F; Pietruck F; Squifflet JP; Segoloni G; Krüger B; Sperschneider H; Banas B; Bäckman L; Weber M; Carmellini M; Perner F; Claesson K; Marcinkowski W; Ostrowski M; Senatorski G; Nordström J; Salmela K
Transplantation; 2012 Sep; 94(5):492-8. PubMed ID: 22858806
[TBL] [Abstract][Full Text] [Related]
26. Tacrolimus, Mycophenolate Mofetil, and Low-Dose Steroids With or Without Interleukin-2 Receptor Antibody Induction Therapy: A Retrospective Cohort Analysis.
Schwarz C; Böhmig G; Steininger R; Unger L; Kristo I; Kozakowski N; Berlakovich GA; Soliman T; Mühlbacher F
Transplant Proc; 2015 Oct; 47(8):2446-9. PubMed ID: 26518948
[TBL] [Abstract][Full Text] [Related]
27. Induction treatment with rabbit antithymocyte globulin versus basiliximab in renal transplant recipients with planned early steroid withdrawal.
Martin ST; Roberts KL; Malek SK; Tullius SG; Vadivel N; De Serres S; Grafals M; Elsanjak A; Filkins BA; Chandraker A; Gabardi S
Pharmacotherapy; 2011 Jun; 31(6):566-73. PubMed ID: 21923440
[TBL] [Abstract][Full Text] [Related]
28. Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial.
Favi E; Spagnoletti G; Salerno MP; Pedroso JA; Romagnoli J; Citterio F
Clin Transplant; 2013; 27(4):E359-67. PubMed ID: 23710603
[TBL] [Abstract][Full Text] [Related]
29. Two corticosteroid-free regimens-tacrolimus monotherapy after basiliximab administration and tacrolimus/mycophenolate mofetil-in comparison with a standard triple regimen in renal transplantation: results of the Atlas study.
Vítko S; Klinger M; Salmela K; Wlodarczyk Z; Tydèn G; Senatorski G; Ostrowski M; Fauchald P; Kokot F; Stefoni S; Perner F; Claesson K; Castagneto M; Heemann U; Carmellini M; Squifflet JP; Weber M; Segoloni G; Bäckman L; Sperschneider H; Krämer BK
Transplantation; 2005 Dec; 80(12):1734-41. PubMed ID: 16378069
[TBL] [Abstract][Full Text] [Related]
30. Two-dose basiliximab compared with two-dose daclizumab in renal transplantation: a clinical study.
Lin M; Ming A; Zhao M
Clin Transplant; 2006; 20(3):325-9. PubMed ID: 16824149
[TBL] [Abstract][Full Text] [Related]
31. Quadruple immunosuppression with basiliximab, tacrolimus, mycophenolate mofetil and prednisone is safe and effective for renal transplantation.
Miura M; Harada H; Fukuzawa N; Iwami D; Taniguchi A; Seki T; Togashi M; Ogawa Y; Satoh H; Hirano T
Clin Transplant; 2005; 19 Suppl 14():54-8. PubMed ID: 15955170
[TBL] [Abstract][Full Text] [Related]
32. Basiliximab and mycophenolate mofetil in combination with low-dose cyclosporine and methylprednisolone effectively prevent acute rejection in kidney transplant recipients.
Kovac D; Kotnik V; Kandus A
Transplant Proc; 2005 Dec; 37(10):4230-4. PubMed ID: 16387086
[TBL] [Abstract][Full Text] [Related]
33. Initial immunosuppression with or without basiliximab: a comparative study.
Martín-Mateos RM; Graus J; Albillos A; Arocena C; Rodríguez Gandía MA; Blesa C; García-Hoz F; García González M; García-Alonso FJ; Bárcena R
Transplant Proc; 2012 Nov; 44(9):2570-2. PubMed ID: 23146457
[TBL] [Abstract][Full Text] [Related]
34. Initial clinical experience with interleukin-2 receptor antagonist induction in combination with tacrolimus, mycophenolate mofetil and steroids in simultaneous kidney-pancreas transplantation.
Lo A; Stratta RJ; Alloway RR; Egidi MF; Shokouh-Amiri MH; Grewal HP; Gaber LW; Gaber AO
Transpl Int; 2001 Dec; 14(6):396-404. PubMed ID: 11793037
[TBL] [Abstract][Full Text] [Related]
35. Basiliximab lowers the cyclosporine therapeutic threshold in the early post-kidney transplant period.
Balbontin F; Kiberd B; Fraser A; Kiberd M; Lawen J
Clin Transplant; 2005 Apr; 19(2):225-9. PubMed ID: 15740559
[TBL] [Abstract][Full Text] [Related]
36. Cardiovascular risk profile in kidney transplant recipients treated with two immunosuppressive regimens: tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine.
Spagnoletti G; Citterio F; Favi E; Rossi E; Delreno F; De Santis I; Salerno MP; Gargiulo A; Castagneto M
Transplant Proc; 2009 May; 41(4):1175-7. PubMed ID: 19460509
[TBL] [Abstract][Full Text] [Related]
37. Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial.
Thomusch O; Wiesener M; Opgenoorth M; Pascher A; Woitas RP; Witzke O; Jaenigen B; Rentsch M; Wolters H; Rath T; Cingöz T; Benck U; Banas B; Hugo C
Lancet; 2016 Dec; 388(10063):3006-3016. PubMed ID: 27871759
[TBL] [Abstract][Full Text] [Related]
38. Comparative study of clinical outcome in kidney transplantation between early steroid withdrawal protocol using basiliximab, calcineurin inhibitor, and mycophenolate mofetil and triple regimen consisting of calcineurin inhibitor, mycophenolate mofetil, and steroid.
Teraoka S; Sato S; Sekijima M; Iwado K; Urashima Y; Kudo S; Kai K; Koyama I; Tojinbara T; Nakajima I; Fuchinoue S
Transplant Proc; 2005 Mar; 37(2):791-4. PubMed ID: 15848533
[TBL] [Abstract][Full Text] [Related]
39. Use of basiliximab with mycophenolate mofetil in kidney transplantation.
Baron PW; Weissman J; Ojogho ON; Sahney S; Cutler D; James S; Oculam C; Abdelhalim F; Nehlsen-Cannarella SL; Teichman S; Concepcion W
Transplant Proc; 2003 Dec; 35(8):2881-4. PubMed ID: 14697927
[TBL] [Abstract][Full Text] [Related]
40. Early steroid withdrawal in a renal transplant cohort treated with tacrolimus, mycophenolate mofetil and basiliximab.
Andrade-Sierra J; Rojas-Campos E; Cardona-Muñoz E; Evangelista-Carrillo LA; Puentes-Camacho A; Lugo-López O; Gómez B; Valdespino C; Cerrillos I; Medina-Pérez M; Jalomo B; Nieves JJ; Sandoval M; Ramos-Solano F; Monteón-Ramos F; Cueto-Manzano AM
Nefrologia; 2014; 34(2):216-22. PubMed ID: 24658197
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
